Camurus AB (publ) – LSE:0RD1.L
Camurus AB (publ) stock price today
Camurus AB (publ) stock price monthly change
Camurus AB (publ) stock price quarterly change
Camurus AB (publ) stock price yearly change
Camurus AB (publ) key metrics
Market Cap | 33.31B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 8.09 |
Revenue | 1.82B |
EBITDA | 585.94M |
Income | 450.47M |
Revenue Q/Q | 37.30% |
Revenue Y/Y | 78.69% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 32.14% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCamurus AB (publ) stock price history
Camurus AB (publ) stock forecast
Camurus AB (publ) financial statements
| Jun 2023 | 674.26M | 301.42M | 44.7% |
|---|---|---|---|
| Sep 2023 | 383.98M | 86.39M | 22.5% |
| Dec 2023 | 374.56M | -15.20M | -4.06% |
| Mar 2024 | 390M | 77.86M | 19.97% |
| 2025 | 3.00B | 1.02B | 33.99% |
|---|---|---|---|
| 2026 | 4.40B | 1.80B | 41.09% |
| 2027 | 6.05B | 2.86B | 47.3% |
| 2028 | 6.94B | 2.97B | 42.88% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1773556000 | 391.67M | 22.08% |
|---|---|---|---|
| Sep 2023 | 1841665000 | 353.35M | 19.19% |
| Dec 2023 | 1907820000 | 414.81M | 21.74% |
| Mar 2024 | 3060750000 | 415.06M | 13.56% |
| Jun 2023 | 66.9M | -4.52M | 2.79M |
|---|---|---|---|
| Sep 2023 | 485.69M | -1.35M | 16.92M |
| Dec 2023 | 30.01M | -2.38M | 11.29M |
| Mar 2024 | 36.32M | -1.63M | 1.04B |
Camurus AB (publ) alternative data
| Aug 2023 | 176 |
|---|---|
| Sep 2023 | 199 |
| Oct 2023 | 199 |
| Nov 2023 | 199 |
| Dec 2023 | 204 |
| Jan 2024 | 204 |
| Feb 2024 | 204 |
| Mar 2024 | 213 |
| Apr 2024 | 213 |
| May 2024 | 213 |
| Jun 2024 | 218 |
| Jul 2024 | 218 |
Camurus AB (publ) other data
| Insider | Compensation |
|---|---|
Mr. Fredrik Tiberg (1963) Chief Executive Officer, Pres, Head of Research & Director | $8,300,000 |
Ms. Eva Pinotti-Lindqvist Chief Financial Officer | |
Mr. Torsten Malmström Chief Technology Officer | |
Mr. Rein Piir B.Sc. Vice President of Investor Relations | |
Mr. Urban Paulsson Vice President of Corporation Devel. & Gen. Counsel | |
Mr. Fredrik Joabsson Chief Bus. Devel. Officer | |
Mr. Richard Jameson Chief Commercial Officer | |
Mr. Peter Hjelmstrom Chief Medical Officer | |
Annette Mattsson Vice President, Regulatory Affairs |
-
What's the price of Camurus AB (publ) stock today?
One share of Camurus AB (publ) stock can currently be purchased for approximately $148.21.
-
When is Camurus AB (publ)'s next earnings date?
Unfortunately, Camurus AB (publ)'s (0RD1.L) next earnings date is currently unknown.
-
Does Camurus AB (publ) pay dividends?
No, Camurus AB (publ) does not pay dividends.
-
How much money does Camurus AB (publ) make?
Camurus AB (publ) has a market capitalization of 33.31B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 79.52% to 1.72B US dollars.
-
What is Camurus AB (publ)'s stock symbol?
Camurus AB (publ) is traded on the LSE under the ticker symbol "0RD1.L".
-
What is Camurus AB (publ)'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Camurus AB (publ)?
Shares of Camurus AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Camurus AB (publ)'s key executives?
Camurus AB (publ)'s management team includes the following people:
- Mr. Fredrik Tiberg Chief Executive Officer, Pres, Head of Research & Director(age: 62, pay: $8,300,000)
- Ms. Eva Pinotti-Lindqvist Chief Financial Officer
- Mr. Torsten Malmström Chief Technology Officer
- Mr. Rein Piir B.Sc. Vice President of Investor Relations
- Mr. Urban Paulsson Vice President of Corporation Devel. & Gen. Counsel
- Mr. Fredrik Joabsson Chief Bus. Devel. Officer
- Mr. Richard Jameson Chief Commercial Officer
- Mr. Peter Hjelmstrom Chief Medical Officer
- Annette Mattsson Vice President, Regulatory Affairs
-
How many employees does Camurus AB (publ) have?
As Jul 2024, Camurus AB (publ) employs 218 workers, which is 2% more then previous quarter.
-
When Camurus AB (publ) went public?
Camurus AB (publ) is publicly traded company for more then 9 years since IPO on 3 May 2016.
-
What is Camurus AB (publ)'s official website?
The official website for Camurus AB (publ) is camurus.com.
-
How can i contact Camurus AB (publ)?
Camurus AB (publ) can be reached via phone at +46 46 286 57 30.
Camurus AB (publ) company profile:
Camurus AB (publ)
camurus.comLSE
225
Medical - Pharmaceuticals
Healthcare
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Lund, 223 70
:
ISIN: SE0007692850
CUSIP: W1970K104
